Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib, Adebrelimab, and GEMOX for Intrahepatic Cholangiocarcinoma
NCT06417606Phase 4Not yet recruiting
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib and adebrelimab in intrahepatic cholangiocarcinoma (ICC). Primary endpoints: Objective Response Rate at 1 year and Disease-Free Survival at 1 year. Planned start May 2024; status: not yet recruiting.
02
Drugs
lenvatinibadebrelimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06417606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417606.